1-10 of 10
Steve Kye
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Activity of Selinexor As a Single Agent and Synergistic Activity with Approved/Investigational Myelofibrosis Therapies in Vitro

Marie E E Maloof, Stephen Wu, Andrea Ellero, Christopher J Walker, Steve Kye, Pietro Taverna
Journal: Blood
Blood (2023) 142 (Supplement 1): 6353.
https://doi.org/10.1182/blood-2023-180134
Published: 2023
Journal Articles

A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor Monotherapy in Patients with JAK Inhibitor-Naïve Myelofibrosis and Moderate Thrombocytopenia (XPORT-MF-044)

Joseph M. Scandura, Aaron T. Gerds, Ellen K. Ritchie, Xulong Wang, Steve Kye, Raajit K. Rampal
Journal: Blood
Blood (2023) 142 (Supplement 1): 3211.
https://doi.org/10.1182/blood-2023-181720
Published: 2023
Journal Articles

A Phase 1 Study of Plamotamab, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma: Recommended Dose Safety/Efficacy Update and Escalation Exposure-Response Analysis

Krish Patel, Peter A. Riedell, Hervé Tilly, Sairah Ahmed, Jean-Marie Michot, Herve Ghesquieres, Jean Marc Schiano de Collela, Asher Chanan-Khan, Kamal Bouabdallah, Benoit Tessoulin, Sunil Iyengar, Meixiao Long, Raphael Clynes, Jitendra Kanodia, Lei Bao, Ying Ding, Jianhua Jin, William B Ainsworth, Raman Garcha, Steve Kye, Tycel J. Phillips
Journal: Blood
Blood (2022) 140 (Supplement 1): 9470–9472.
https://doi.org/10.1182/blood-2022-159586
Published: 2022
Journal Articles

Phase 2 Randomized, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of Plamotamab Combined with Tafasitamab (Tafa) + Lenalidomide (Len) Vs Tafa+Len in Relapsed or Refractory DLBCL

Krish Patel, Youngil Koh, Sabarish Ayyappan, Yasmin Karimi, Izidore S. Lossos, Akil Merchant, Phuong Lee, Jianhua Jin, Raphael Clynes, Jitendra Kanodia, Michael T. Chiarella, Steve Kye, Jean-Marie Michot
Journal: Blood
Blood (2022) 140 (Supplement 1): 12066–12067.
https://doi.org/10.1182/blood-2022-158042
Published: 2022
Journal Articles

Real-World Management of Patients with Newly Diagnosed Acute Myeloid Leukemia Treated with Venetoclax-Based Regimens: Results from the AML Real World Evidence (ARC) Initiative

Pankit Vachhani, Ofir Wolach, Jacqueline S. Garcia, Joshua F. Zeidner, Chetasi Talati, Daniel A. Pollyea, Catherine Lai, Yakir Moshe, Sameem Abedin, David Lavie, Tsila Zuckerman, Marin Xavier, Sangmin Lee, Evan Chen, Wesleigh Edwards, Cat N. Bui, Anders Svensson, Steve Kye, Rebecca Burne, Jessica Maitland, Esprit Ma, Melissa Montez, Moshe Grunspan, Aaron D Goldberg
Journal: Blood
Blood (2021) 138 (Supplement 1): 1271.
https://doi.org/10.1182/blood-2021-151586
Published: 2021
Journal Articles

Venetoclax and Azacitidine in the Treatment of Patients with Relapsed/Refractory Myelodysplastic Syndrome

Amer M. Zeidan, Uma Borate, Daniel A. Pollyea, Andrew M. Brunner, Fernando Roncolato, Jacqueline S. Garcia, Robin J Filshie, Olatoyosi Odenike, Anne-Marie Watson, Ravi Krishnadasan, Ashish Bajel, Kiran Naqvi, Jiuhong Zha, Leah Hogdal, Ying Zhou, David Hoffman, Steve Kye, Guillermo Garcia-Manero
Journal: Blood
Blood (2021) 138 (Supplement 1): 537.
https://doi.org/10.1182/blood-2021-145646
Published: 2021
Journal Articles

Comparative Effectiveness of Venetoclax Combinations Vs Other Therapies Among Patients with Newly Diagnosed Acute Myeloid Leukemia: Results from the AML Real World Evidence (ARC) Initiative

Jacqueline S. Garcia, Ofir Wolach, Pankit Vachhani, Joshua F. Zeidner, Chetasi Talati, Daniel A. Pollyea, Catherine Lai, Yakir Moshe, Sameem Abedin, David Lavie, Tsila Zuckerman, Marin Xavier, Sangmin Lee, Wesleigh Edwards, Evan Chen, Cat N. Bui, Anders Svensson, Rebecca Burne, Steve Kye, Jessica Maitland, Esprit Ma, Melissa Montez, Moshe Grunspan, Aaron D Goldberg
Journal: Blood
Blood (2021) 138 (Supplement 1): 2328.
https://doi.org/10.1182/blood-2021-151285
Published: 2021
Journal Articles

Molecular Responses Are Observed across Mutational Spectrum in Treatment-Naïve Higher-Risk Myelodysplastic Syndrome Patients Treated with Venetoclax Plus Azacitidine

Jacqueline S. Garcia, Andrew H. Wei, Meagan A. Jacoby, Chun Yew Fong, Uma Borate, Maria R. Baer, Ilona Cunningham, Olatoyosi Odenike, Joseph G. Jurcic, Daniel Nowak, Pierre Peterlin, Uwe Platzbecker, Diana Dunshee, Ying Zhou, David Hoffman, Yan Sun, Relja Popovic, Barrett Ainsworth, Kiran Naqvi, Steve Kye, Leah Hogdal, Guillermo Garcia-Manero
Journal: Blood
Blood (2021) 138 (Supplement 1): 241.
https://doi.org/10.1182/blood-2021-145613
Published: 2021
Journal Articles

Characteristics and Outcomes of Newly Diagnosed Acute Myeloid Leukemia Patients Receiving Venetoclax Combinations Vs Other Therapies: Results from the AML Real World Evidence (ARC) Initiative

Daniel A. Pollyea, Maximilian Stahl, Chetasi Talati, MD, Hannah Asghari, MD BS, Catherine Lai, MD MPH, Sameem Abedin, MD, Joshua F. Zeidner, MD, Benyam Muluneh, PharmD, Marin Xavier, Wesleigh Edwards, MD PhD, Ofir Wolach, MD, Yakir Moshe, MDPhD, David Lavie, MD, Tsila Zuckerman, MD, Michelle Choi, Cat N. Bui, PhD, Anders Erik Svensson, MD, Steve Kye, MD MPH, Rebecca Burne, Annie Guerin, MSc, Esprit Ma, Melissa Montez, Aaron D Goldberg, MDPhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 26–28.
https://doi.org/10.1182/blood-2020-134789
Published: 2020
Journal Articles

Safety, Efficacy, and Patient-Reported Outcomes of Venetoclax in Combination with Azacitidine for the Treatment of Patients with Higher-Risk Myelodysplastic Syndrome: A Phase 1b Study

Jacqueline S. Garcia, MD, Andrew H. Wei, Uma Borate, Chun Yew Fong, MBBS, PhD FRACP, FRCPA, Maria R. Baer, MD, Florian Nolte, MD, Joseph G. Jurcic, MD, Meagan A. Jacoby, MD, Wan-Jen Hong, MD, Uwe Platzbecker, Olatoyosi Odenike, MD, Ilona Cunningham, MBBS, FRACP, FRCPA, Ying Zhou, PhD, Bo Tong, PhD, Leah Hogdal, PhD, Rajesh Kamalakar, MS, Jessica E. Hutti, PhD, Steve Kye, MD MPH, Guillermo Garcia-Manero, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 55–57.
https://doi.org/10.1182/blood-2020-139492
Published: 2020